Compare CARS & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | AQST |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.1M | 504.0M |
| IPO Year | 2017 | 2007 |
| Metric | CARS | AQST |
|---|---|---|
| Price | $9.94 | $4.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $16.00 | $9.00 |
| AVG Volume (30 Days) | 774.4K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $723,239,000.00 | $67,430,000.00 |
| Revenue This Year | $3.03 | $10.08 |
| Revenue Next Year | $2.57 | $49.60 |
| P/E Ratio | $122.25 | ★ N/A |
| Revenue Growth | 0.57 | ★ 0.77 |
| 52 Week Low | $7.40 | $2.64 |
| 52 Week High | $13.97 | $7.55 |
| Indicator | CARS | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 45.24 |
| Support Level | $7.64 | $4.00 |
| Resistance Level | $12.54 | $4.38 |
| Average True Range (ATR) | 0.48 | 0.20 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 17.07 | 7.21 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.